Arcadia Biosciences (RKDA) Accumulated Expenses (2014 - 2025)

Arcadia Biosciences has reported Accumulated Expenses for 12 years, with the latest figure at $107000.0 in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses rose 2040.0% year-over-year to $107000.0; the trailing twelve-month figure through Dec 2025 stood at $107000.0 (up 2040.0% YoY), and the FY2025 full-year result was $107000.0, up 2040.0% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $107000.0, up from $5000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $1.6 million in Q4 2021, with the low at $5000.0 in Q4 2024.
• Historically, Accumulated Expenses has averaged $568600.0 across 5 years, with a median of $107000.0 in 2025.
• Annual changes were most pronounced in 2022 — Accumulated Expenses tumbled 99.63% — and 2023, when it soared 18550.0%.
• Arcadia Biosciences' Accumulated Expenses stood at $1.6 million in 2021, then plunged by 99.63% to $6000.0 in 2022, then soared by 18550.0% to $1.1 million in 2023, then slumped by 99.55% to $5000.0 in 2024, then surged by 2040.0% to $107000.0 in 2025.
• The last three Accumulated Expenses figures came in at $107000.0 (Q4 2025), $5000.0 (Q4 2024), and $1.1 million (Q4 2023), per Business Quant data.